Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, announced today the second closing of its Series A financing of $17 million USD, bringing the total raised to $33 million in this round. The funding will support the advancement of Mogrify’s immuno-oncology and...
Mogrify will transform the development of life saving cell therapies via the licence of proprietary cell conversions tailored to any therapeutic application
Telephone: 01223 734154
25 Cambridge Science Park Milton Rd Cambridge
Post Code: CB4 0FW
Country: United Kingdom
Membership Type: Corporate 21-50